Seeking Alpha

St. Jude Medical, Inc. (STJ)

  • Tue, Jul. 21, 12:41 PM
  • Feb. 10, 2014, 11:19 AM
  • Jan. 22, 2014, 9:18 AM
  • Jan. 6, 2014, 2:09 PM
  • Nov. 5, 2013, 2:54 PM
  • Oct. 10, 2013, 9:45 AM
  • Oct. 4, 2013, 1:46 PM
  • Jun. 12, 2013, 1:07 PM
    Deutsche Bank (Buy) thinks the approval of St. Jude Medical's (STJ +2.6%) implantable cardioverter and cardiac resynchronization defibrillators is a "good sign," as it may signal that STJ is "making progress" with its efforts to allay concerns tied to an FDA inspection of the company's Sylmar, California manufacturing facility. Wedbush's Tao Levy concurs, noting that the FDA "viewed the safety enhancements of the Ellipse and Assura as important enough to approve despite the warning letter."
    | Comment!
  • Mar. 8, 2013, 2:55 PM
    St. Jude Medical (STJ +1.1%) is up today after the company reports the first patient implant in a new trial evaluating the company's Aplatzer Cardiac Plug, a device for the prevention of stroke. The trial is designed to determine if the device is safe and effective in preventing thrombus from migrating out of the left atrial appendage in patients with non-valvular atrial fibrillation who have a high risk for stroke.
    | Comment!
  • Feb. 15, 2013, 2:10 PM
    St. Jude Medical (STJ -3.4%) has been working overtime to convince the Street that its Durata heart device leads are safe, but Cowen doesn't take the bait, downgrading the stock to Market Underperform over concerns that the new heart wire is no different from the ones already taken off the market. The firm cites a "significant risk" of a recall, which would " meaningfully damage" its defibrillator and pacemaker business.
    | Comment!
  • Jan. 15, 2013, 2:22 PM
    Boston Scientific (BSX +2.5%) hits a 16-month high today after Credit Suisse upped the stock to Outperform, citing a better top-line and improved visibility. On those catalysts, the firm reduces the valuation discount it thinks the stock should trade at versus rivals St. Jude (STJ) and Medtronic (MDT) to 10%. The stock currently trades at around a 20% discount to its peers.
    | Comment!
  • Nov. 30, 2012, 11:27 AM
    St. Jude Medical (STJ +1.4%) gains on the back of yesterday's $1B buyback announcement and an upgrade to Buy at Mizuho. The firm says that concerns about a Durata recall are overblown, and that any impact on its EPS from market share loss in implanted defibrillators should be "more than offset" by yesterday's buyback announcement.
    | Comment!
  • Nov. 26, 2012, 11:01 AM
    Boston Scientific (BSX +2.7%) bucks a down tape this morning on an upgrade to Buy at Citigroup. The firm says BSX is positioned to be the biggest winner from St. Jude Medical's (STJ -1%) Durata troubles. Citi expects it will be taken off the market within six months, and the ripple effects are likely to cost STJ around $820M in annual sales. BSX could easily take 41% of that market share, with Medtronic (MDT -0.9%) absorbing around 29%. Citi's upgrade differs widely from comments made on Friday by BofA Merrill, which put the risk of a Durata recall well below 50%.
    | Comment!
  • Nov. 23, 2012, 11:50 AM
    Shares of St. Jude Medical (STJ +3%) claw back a bit of their 12% pummeling taken on Wednesday following the FDA's release of a report citing serious flaws in STJ's oversight of Durata. BofA Merrill Lynch notes that the report found no new safety issues and the probability of a recall stands well below 50%, which is already priced into the stock. It reiterates a Buy with a potential downside to $24 and an upside peaking around $40.
    | Comment!
  • Nov. 21, 2012, 12:45 PM
    Midday top 10 gainers: MEMS +72%. NLP +38%. ARCI +20%. INFI +14%. VVUS +14%. NCTY +13%. SKX +12%. SQNM +11%. PSUN +11%. MTSL +11%. Midday top 10 Losers: STV -46%. ZLC -29%. CNET -18%. SCHL -18%. TLYS -17%. STJ -14%. CLNT -13%. EBR -11%. HGSH -11%. KID -11%.
    | 1 Comment
  • Nov. 19, 2012, 2:23 PM
    St. Jude Medical (STJ +2%) says its received European approval for its Portico heart valve replacement device. The approval gives STJ access to a burgeoning market for the devices, and the news gives a much-needed lift to the stock after a string of negative headlines in recent months has driven the stock down near 52-week lows. Since October alone, STJ has shaved nearly 17% off its market cap.
    | Comment!
Visit Seeking Alpha's
STJ vs. ETF Alternatives
Company Description
St Jude Medical Inc develops, manufactures and distributes cardiovascular medical devices for global cardiac rhythm management, cardiovascular, atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain.